MLL translocations specify a distinct gene expression profile, distinguishing a unique leukemia
US7011947B2 · kind B2 · utility
17Cited by
3References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 17, 2002 |
| Grant date | Mar 14, 2006 |
| Priority date | — |
| Expiry date | Jun 14, 2023 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to the diagnosis of mixed lineage leukemia (MLL), acute lymphoblastic leukemia (ALL), and acute myelogenous leukemia (AML) according to the gene expression profile of a sample from an individual, as well as to methods of therapy and screening that utilize the genes identified herein as targets.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.